Sava Infond d.o.o. Invests $1.54 Million in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sava Infond d.o.o. purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,960 shares of the medical research company’s stock, valued at approximately $1,540,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Legacy Investment Solutions LLC purchased a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $26,000. Barrett & Company Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $28,000. FPC Investment Advisory Inc. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $28,000. Missouri Trust & Investment Co bought a new stake in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Finally, Pillar Financial Advisors LLC bought a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. 89.23% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock valued at $13,106,062 in the last ninety days. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TMO. Scotiabank raised their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a report on Monday, February 3rd. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a research report on Friday, January 10th. Royal Bank of Canada set a $693.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 31st. Wells Fargo & Company increased their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Finally, Raymond James restated an “outperform” rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Four research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $653.23.

Thermo Fisher Scientific Stock Down 0.2 %

TMO opened at $513.40 on Thursday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $193.68 billion, a PE ratio of 31.06, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52 week low of $493.30 and a 52 week high of $627.88. The firm has a 50-day simple moving average of $543.80 and a two-hundred day simple moving average of $553.93.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.43 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.34%. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.